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The effects of myelin 
on macrophage activation are 
phenotypic specific via  cPLA2 
in the context of spinal cord injury 
inflammation
Timothy J. Kopper, Bei Zhang, William M. Bailey, Kara E. Bethel & John C. Gensel* 
Spinal cord injury (SCI) produces chronic, pro-inflammatory macrophage activation that impairs 
recovery. The mechanisms driving this chronic inflammation are not well understood. Here, we 
detail the effects of myelin debris on macrophage physiology and demonstrate a novel, activation 
state-dependent role for cytosolic phospholipase-A2  (cPLA2) in myelin-mediated potentiation of 
pro-inflammatory macrophage activation. We hypothesized that  cPLA2 and myelin debris are key 
mediators of persistent pro-inflammatory macrophage responses after SCI. To test this, we examined 
spinal cord tissue 28-days after thoracic contusion SCI in 3-month-old female mice and observed 
both  cPLA2 activation and intracellular accumulation of lipid-rich myelin debris in macrophages. 
In vitro, we utilized bone marrow-derived macrophages to determine myelin’s effects across a 
spectrum of activation states. We observed phenotype-specific responses with myelin potentiating 
only pro-inflammatory (LPS + INF-γ; M1) macrophage activation, whereas myelin did not induce pro-
inflammatory responses in unstimulated or anti-inflammatory (IL-4; M2) macrophages. Specifically, 
myelin increased levels of pro-inflammatory cytokines, reactive oxygen species, and nitric oxide 
production in M1 macrophages as well as M1-mediated neurotoxicity. PACOCF3  (cPLA2 inhibitor) 
blocked myelin’s detrimental effects. Collectively, we provide novel spatiotemporal evidence 
that myelin and  cPLA2 play an important role in the pathophysiology of SCI inflammation and the 
phenotype-specific response to myelin implicate diverse roles of myelin in neuroinflammatory 
conditions.
Abbreviations
AA  Arachidonic acid
BMDM  Bone marrow-derived macrophage
cPLA2  Cytosolic phospholipase A2




MCM  Macrophage conditioned media
P/S  Penicillin/streptomycin
ROS  Reactive oxygen species
RPMI  Roswell Park Memorial Institute medium
SCI  Spinal cord injury
Spinal cord injury (SCI) triggers a complex neuroinflammatory response that mediates tissue repair but also 
potentiates secondary injury processes. Activated macrophages, consisting of resident microglia and infiltrating 
monocytes, contribute to this dichotomous response. Macrophages facilitate repair by increasing axon growth, 
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stem cell differentiation, and  revascularization1,2, however, macrophages can also contribute to pathology through 
secondary injury processes involving reactive oxygen species (ROS), neurotoxins, and pro-inflammatory cytokine 
release as well as by causing axon retraction and  dieback1,3. The extent to which macrophages are polarized 
toward reparative (also called M2 or anti-inflammatory) or pathological (also called M1 or pro-inflammatory) 
phenotypes largely depends on the stimuli present in the injured spinal cord.
One notable distinction between SCI and self-resolving peripheral nerve injuries is the sustained presence of 
myelin debris. Lipid-laden myelin debris is taken up and processed predominantly by infiltrating macrophages, 
rather than endogenous microglia, after  SCI4. Phagocytic markers are present on these chronically activated 
macrophages, which become visibly laden with  debris4–8. It is therefore likely that myelin lipids are actively pro-
cessed by macrophages and are environmental stimuli that drive chronic spinal cord inflammation. Indeed, in 
areas of Wallerian degeneration, macrophages disappear from the chronically injured spinal cord concomitant 
with myelin debris  clearance4–6,9. The accumulation of lipid debris in the days and weeks after injury also closely 
aligns with the temporal shift in macrophage phenotype, ending with persistent pro-inflammatory activation by 
28  dpi2,4. Evidence also suggests that myelin acts as an inflammatory stimulus on macrophages in vitro, impli-
cating a key link between myelin debris accumulation and the grievous shift in macrophage phenotype which 
impairs regeneration after  SCI4,7,10,11.
While myelin debris is implicated in macrophage activation state and recovery after  SCI4,7,12, the intracel-
lular mechanisms mediating myelin’s effects remain unclear. Cytosolic phospholipase A2  (cPLA2) facilitates 
arachidonic acid (AA) release from cellular membranes following inflammatory stimuli and is largely unstudied 
in SCI macrophage responses. Interestingly, myelin membranes contain high concentrations of AA, stored in 
its inactive esterified state; however, whether  cPLA2 can act on these lipids remains unknown.  cPLA2-mediated 
breakdown of AA initiates an eicosanoid storm in which a wide variety of bioactive lipids are released including 
prostaglandins, leukotrienes, and thromboxanes. Eicosanoids have diverse albeit largely pro-inflammatory func-
tions including activating the inflammatory NF-kB signaling cascade and increasing edema as well as potentiating 
immune cell chemoattraction, fibrosis, and inflammatory responses. The role of  cPLA2 in macrophage physiology 
has been detailed in other systems; however, it is unknown if  cPLA2 has any differential effects in macrophages 
polarized along the spectrum of activation states in the presence of myelin, or if it is a contributor to prolonged 
pro-inflammatory activation of macrophages after SCI.  cPLA2 activation is induced by inflammatory stimuli 
such as LPS/IFN-γ, also known as the M1, pro-inflammatory paradigm in vitro, and is likely induced by the 
complex inflammatory environment observed after  SCI13–15. This is the basis of our hypothesis that  cPLA2 activ-
ity in myelin-laden macrophages after SCI aggravates tissue damage and contributes to chronic inflammation. 
Here we establish these mechanisms in vitro, and provide the proof-of-concept that these pathways may play an 
important role in vivo after SCI.
Methods
Animals. As described  previously16,17, in  vitro experiments were performed using 2–4-month-old female 
C57BL/6 mice (Jackson Laboratory, Bar Harbor, Maine). In vivo experiments were performed using 4-month-
old female C57BL/6 mice, weighing 20.7 g ± 1.3 g (Jackson Laboratory, Bar Harbor, ME, USA). Animals were 
housed in IVC cages with ad libitum access to food and water. All procedures were performed in accordance 
with the guidelines and protocols of the Office of Research Integrity and with approval of the Institutional Ani-
mal Care and Use Committee at the University of Kentucky. All experiments were carried out in compliance with 
the ARRIVE  guidelines18.
Cell culture. Bone marrow-derived macrophages (BMDMs) were extracted from the femur and tibia of 
female C57BL/6 mice at 2–4 months old as previously  reported19,20 and were plated at 0.8–1 ×  106 cells/mL in 
differentiation media containing Roswell Park Memorial Institute medium (RPMI, Thermo Fisher Scientific, 
#21870-092) supplemented with 1% penicillin/streptomycin (P/S, Thermo Fisher Scientific, #5140122), 1% 
HEPES (Sigma-Aldrich, #83264-100ML-F), 1% GlutaMAX 0.001 (Thermo Fisher Scientific, #35050061) 0.001% 
β-mercaptoethanol (Thermo Fisher Scientific, #21985023), 10% FBS (Life technologies, #10082147), and 20% 
supernatant from sL929 cells (a generous gift from Phillip Popovich, The Ohio State University). Supernatant 
collected from sL929 cells contains macrophage colony-stimulating factor, which helps to promote bone marrow 
cells’ differentiation into  macrophages21. The BMDMs were allowed to differentiate for 7 days in culture, and 
cells were then replated on day 7 at a density of 1 ×  106 cells/mL in 12-well plates in RPMI, containing 1% P/S, 1% 
GlutaMAX and 10% FBS. On day 8, cells were stimulated for 24 h to be either M1 using LPS (50 ng/mL, Invivo-
gen, #tlrl-eblps, standard preparation) plus IFN-γ (20 ng/ml, eBioscience #14-8311-63) diluted in N2A growth 
medium (described below), M2 using IL-4 (20 ng/ml, R&D systems, #404-ML-010), or Control/Unstimulated 
(CTL) using fresh media without any stimulants. At the time of stimulation cells were immediately treated with 
myelin debris (50 µL/mL, preparation described below), 50 µM PACOCF3 (inhibitor of  cPLA2, Tocris Biosci-
ence, CAS 141022-99-3), or PBS/DMSO vehicles to equalize volume and drug solvent concentrations across 
groups. 24  h after stimulation the supernatants were removed, centrifuged at 13,000 RPM (Fisher Scientific 
accuSpin Micro R centrifuge), and then this macrophage conditioned media (MCM) was either applied directly 
to N2A cells to measure cytotoxicity, or stored at − 80 °C prior to testing for IL-12p40 levels using standard 
ELISA kits (Thermo Fisher Scientific, Rockford, IL # EMIL12P40), Nitric Oxide with the Griess Reagent Kit 
(Thermo Fisher Scientific # G-7921), and phenol red-free RPMI, or a mulit-plex ELISA system measuring pro-
tein levels of TNF-alpha, IL-1Beta, IL-6, CX3CL1, and IL-10 (Meso Scale Diagnostics). BMDMs for coverslip 
stains were treated as above, except at a lower plating density of 3 ×  105 cells/mL. Coverslips were fixed in cold 
2% PFA for 30 min, washed in PBS and stored at 4 °C until staining.
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Moderate purity myelin (> 95% myelin, with small contributions from axolemma and other cellular mem-
branes) was prepared as follows (adapted from Larocca et al.22): brains were collected from C57BL/6 mice at the 
time of BMDM isolation and stored at − 80 °C prior to myelin isolation. The brains were rinsed and suspended 
in cold PBS with 1% P/S and placed in a Dounce homogenizer (DWK Life Science, #357544) under sterile con-
ditions and blended with the loose and tight pestles. The solution was transferred to a 15 mL tube and pelleted 
at 2000 RPM (Thermo Scientific Legend XTR centrifuge) prior to discarding the soluble supernatant fraction. 
The pellet was resuspended in the PBS/P/S, and then 5mLs of a 30% Percoll solution (Sigma-Aldrich, #P1644-
500ML) was gently underlaid below the myelin solution for density gradient centrifugation. The layers were then 
centrifuged at 2000 RPM for 15 min at 4 °C under gentle acceleration/deceleration, generating three distinct 
layers (soluble on top, myelin in middle, and Percoll/cell pellet on bottom). After removing the soluble fraction, 
the myelin was transferred to a fresh tube and resuspended in 10 mL distilled water with 1% P/S and incubated 
for 10 min (hypoosmotic shock) to separate membranes at 4 °C. The myelin was then re-pelleted at 2000 RPM, 
suspended in PBS/1% P/S and separated a second time by density gradient centrifugation as described above. 
The myelin was then suspended and pelleted twice in PBS/1% P/S to remove residual Percoll and water-soluble 
contaminants, and then aliquoted before storage at − 80 °C. The final protein concentration of the myelin stock 
solutions produced by this protocol were 10.23 mg/mL with a standard deviation of 0.282 mg/mL as determined 
by a BCA Protein Assay Kit (Thermo Fisher Scientific #23225). With the application of myelin debris to BMDMs 
at 50 µL/mL, cells had a mean dosage of 0.51 mg/mL. Lastly, to ensure our results were not due to endotoxin 
contamination in our myelin preparations, we tested aliquots from each batch of myelin stimulant (Thermo 
Fisher Scientific #88282).
A mouse neuroblastoma cell line (Neuro-2a or N2A, a gift from Chris Richards, University of Kentucky) 
was maintained in N2A growth medium containing 45% DMEM, 45% OPTI-MEM reduced-serum medium, 
10% fetal bovine serum (FBS), and 1% penicillin/streptomycin. N2A were plated at a density of 1 ×  105 cells/
mL in 96-well tissue culture plates and allowed to proliferate for 48 h. The neurotoxicity of MCM was evalu-
ated as reported previously using a MTT-based cell growth determination kit according to the manufacturer’s 
instructions (Sigma-Aldrich CGD1-1KT)23. Briefly, 24 h before testing, N2A growth media was replaced with 
serum-free N2A media to induce differentiation. The day of testing this media was replaced by fresh MCM, and 
the N2A cells were incubated in MCM for 24 h before thiazolyl blue tetrazolium bromide (MTT (5 mg/ml), 
20 μl per well) was added to each well and the cells further incubated for 2 h. The tetrazolium ring of MTT can 
be cleaved by mitochondrial dehydrogenases of viable cells, yielding purple formazan crystals, which were then 
dissolved in acidified isopropanol solvent. The resulting purple solution was spectro-photometrically measured 
at 570 nm Epoch microplate reader (BioTek Instruments, Inc., Winooski, VT) using 690 nm as a background 
absorbance. This data is normalized to the non-toxic CTL values to generate proportional decrease in viability 
values and presented inversely as increased toxicity relative to CTL.
Macrophage reactive oxygen species (ROS) production was measured using CM-H2DCFDA (Invitro-
gen #C6827). In short, BMDMs were cultured and stimulated as described above except in a 96 well plate 
(1 ×  106 cells/mL). Following the 24-h stimulation the supernatants were removed and replaced with a 5 µM 
solution of CM-H2DCFDA in phenol red-free RPMI with 1% GlutaMAX and penicillin/streptomycin and incu-
bated at 37 °C for 25 min. ROS mediates the conversion of this compound to fluorescent DCF which was then 
detected by an Epoch microplate reader (BioTek instruments, Inc., Winooski, VT) at the compound’s Excitation/
Emission spectra of approx. 492–495/517–527 nm.
Macrophage  cPLA2 activity was measured using a Cytosolic Phospholipase A2 Assay Kit (Abcam #ab133090). 
In short, cells were cultured as described above except in six well culture dishes (1 ×  106 cells/mL). Cells were lysed 
and briefly sonicated on ice in TBS-T (0.4% Triton-X) with a protease inhibitor (Sigma-Aldrich #11836170001) 
before proceeding directly into the manufacturer’s protocol.
Spinal cord injury. As described  previously16,17, animals were anesthetized via intraperitoneal (i.p.) injec-
tions of ketamine (100 mg/kg) and xylazine (10 mg/kg). Following a T9 laminectomy, a moderate-severe tho-
racic SCI was produced using the Infinite Horizon (IH) injury device (75-kdyn displacement; Precision Systems 
and Instrumentation). Any animals receiving SCI with abnormalities in the force vs. time curve generated by the 
IH device were excluded from analysis. These abnormalities are indicative of bone hits or instability in the spinal 
cord at the time of injury and occurred < 10% of the time. After injury, muscle and skin incisions were closed 
using monofilament suture. After surgery, animals received one subcutaneous injection of buprenorphine-SR 
(1 mg/kg) and antibiotic (5 mg/kg, enroloxacin 2.27%: Norbrook Inc., Lenexa, KS) in 2 mL of saline and were 
housed in warming cages overnight. Animals continued to receive antibiotic subcutaneously in 1 mL saline for 
5 days. Food and water intake and the incision site were monitored throughout the course of the study. Bladder 
expression was performed on injured mice twice daily. Mice were sacrificed at 7 and 28 days post-injury (n = 8 
and 10, respectively) to generate spinal cord sections for histological analyses.
Tissue processing and immunohistochemistry. As described  previously16,17, mice were anesthetized 
and then transcardially perfused with cold PBS (0.1 M, pH 7.4), followed by perfusion with cold 4% paraform-
aldehyde (PFA). Dissected spinal cords (1 cm) were post-fixed for another 2 h in 4% PFA and subsequently 
rinsed and stored in cold phosphate buffer (0.2 M, pH 7.4) overnight at 4 °C. On the following day, tissues were 
cryoprotected in 30% sucrose for 3 days at 4 °C, followed by rapidly freezing and blocking in optimal cutting 
temperature (OCT) compound (SakuraFinetek USA, Inc.) on dry ice. Tissue blocks were cut in serial coronal 
sections (10 μm) and mounted onto Colorfrost plus slides (Fisher #12-550-17).
Spinal cord sections were stained with Eriochrome Cyanine (myelin) and anti-Neurofilament (1:1000, Aves 
labs, NFH) to visualize damage and thereby identify the epicenter of each lesion, as defined as the point where 
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spared tissue constitutes the smallest proportion of spinal cord  volume16. Immunohistochemistry on tissue sec-
tions and BMDM coverslips was performed to stain for phosphylated-cPLA2 (p-cPLA2; rabbit, 1:500, Cell Signal-
ing Technology #2831S), BODIPY (2 µM 30 min, Thermo Fisher Scientific #D3922), biotinylated tomato lectin 
(TomL) (Sigma-Aldrich L0651-1MG, and DAPI (Sigma-Aldrich #D9542-10MG) overnight at 4 °C. Secondary 
antibodies were applied at 1:1000 for 1 h at RT: Alexa Fluor 546 goat anti-rabbit (Life Technologies #11010), and 
Streptavidin Alexa Fluor 647 conjugate (Thermo Fisher Scientific #S-21374). Antigen retrieval was performed 
to improve signal: 10 min in sodium citrate buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6.0) at 90 °C. 
BODIPY is specific to neutral lipids from the breakdown of myelin and cellular membranes. TomL binds to 
poly-N-acetyl lactosamine on macrophages and microglia. TomL also binds to large blood vessels which were 
excluded from analysis when possible based on their large tubular  morphology24,25. Imaging was performed at 
or within 100 µm of lesion epicenter due to tissue loss during antigen retrieval. All images were taken using a 
C2+ laser scanning confocal microscope (Nikon Instruments Inc., Melville, NY, USA). Images were quantified 
using using the MetaMorph analysis program (Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis. As described  previously16,17 statistical analyses were completed using GraphPad Prism 
6.0 (GraphPad Software). Data were analyzed using one- or two-way ANOVA followed by Dunnett’s test for 
multiple comparisons. Results were considered statistically significant at p ≤ 0.05. All data are presented as 
mean ± SEM unless otherwise noted. All in vitro measurements were done in triplicates, and at least three inde-
pendent experiments were carried out. Imaging and quantification were performed by investigators fully blinded 
to all experimental conditions. In vitro experiments were not fully blinded during experimental procedures (due 
to the obvious presence of myelin in some conditions); however, all analyses were confirmed by an investigator 
blinded to experimental conditions. Figures were prepared using Adobe Photoshop CS6 (Adobe Systems) and 
Prism 6.0.
Results
Myelin-laden macrophages contain active  cPLA2 after SCI. In order to determine the extent to 
which  cPLA2 may be contributing to myelin processing by macrophages after SCI, we examined inflamma-
tion within the injured spinal cord 4 weeks after mouse contusion SCI. As reported  previously4, we observed 
that SCI generated extensive infiltration of monocyte derived macrophages and activation of resident microglia 
(Fig. 1A,F,K). Similarly, we observed presumptive myelin debris, i.e. neutral lipid droplets detected by BODIPY 
staining inside TomL+ macrophages throughout the injury epicenter (Fig. 1B,G,L). Extracellular lipid droplets 
not clearly contained within macrophages were also present (Fig. 1B,G,L). Next, we sought to determine whether 
the  cPLA2 system is active (phosphorylation indicates activation) in these chronically activated macrophages 
within the injured spinal cord. As indicated in Fig. 1C,H,M,  cPLA2 is widely activated (p-cPLA2) throughout the 
lesion epicenter images of macrophages, and critically is observed within macrophages containing lipid debris 
at 28 days after injury (dpi). Similar observations were also seen at 7 dpi (Supplemental Fig. 1). Lastly, uninjured 
tissue from sham surgery animals contained TomL+ macrophage/microglia populations but no appreciable lipid 
debris, and minimal  cPLA2 activation (Fig. 1P–T). Collectively this provides spatiotemporal evidence that mac-
rophages are chronically present in the injured spinal cord, loaded with substantial myelin-derived lipid debris, 
and can contain activated  cPLA2. Furthermore, these results provide the proof-of-concept that myelin and  cPLA2 
may play a key role in the prolonged pro-inflammatory macrophage activation thought to impede semi-acute 
and chronic recovery after SCI.
Myelin potentiates pro-inflammatory macrophage activation in an activation state depend-
ent manner. To determine the role of myelin in the activation of macrophages we developed an in vitro 
model of SCI inflammation. BMDMs are predictive of monocyte-derived macrophage responses in vivo in the 
injured spinal cord. This have been observed at  transcription26 and functional  levels19, as well as in response to 
therapeutic  interventions27. Further, BMDMs are the primary myeloid cells phagocytizing myelin after  SCI4. 
Specifically, we used an M1 stimuli (LPS + IFN-γ) to model the detrimental pro-inflammatory activation state, 
M2 (IL-4) to model the reparative anti-inflammatory activation state, and CTL (unstimulated control or M0) 
to model a mature, yet naïve macrophage. Myelin stimulation was generated from mouse CNS tissue to model 
the myelin debris “stimulant” generated after SCI in vivo. Using this system, we observe both myelin up-take 
across activation states and increased  cPLA2 activation under M1 conditions (p < 0.001) (Supplementary Fig. 2). 
Interestingly, we observed that many of myelin’s effects on macrophage physiology were activation state depend-
ent, with differential effects when applied in the M1, M2, or CTL activation states. In Fig. 2A, pro-inflammatory 
(M1) macrophages had increased production of the pro-inflammatory cytokine IL-12 compared to unstimulated 
(CTL) or anti-inflammatory (M2) macrophages, as would be expected (p < 0.001). Upon the concurrent addition 
of myelin to these groups, however, the M1 production of IL-12 rises substantially (p < 0.01), whereas CTL and 
M2 cells were not significantly affected. In Fig. 2B,C we performed additional stimulations and measured the 
production of reactive oxygen species (ROS) and nitric oxide, two toxic macrophage byproducts thought to con-
tribute to cell death and SCI pathogenesis. With this, we observed a similar phenotype-specific effect in which 
only pro-inflammatory M1 cells were significantly potentiated by the addition of myelin, whereas CTL and M2 
cells were not significantly affected. Specifically, M1 stimulation significantly increased levels of ROS (p < 0.001), 
and nitric oxide relative to unstimulated (CTL) cells, as would be expected. Critically, each of these M1 mediated 
increases were significantly increased with the application of myelin alongside the M1 stimulation, indicating 
that myelin potentiates pro-inflammatory responses (p < 0.001 and p < 0.001, respectively). Interestingly, this 
novel phenomenon occurred despite observing similar degrees of myelin debris uptake across all treatment 
groups (Supplemental Fig. 2), suggesting that differences in phagocytosis is not a contributing factor. The mech-
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anisms through which the myelin was taken up under each phenotype, however, was not evaluated. To test the 
effects of myelin on an anti-inflammatory associated functional outcome we examined the activity of the argin-
ase-1 enzyme in cell lysates from each of our stimulations (Fig. 2D). As would be expected, M2 macrophages had 
higher arginase activity relative to M1 and CTL (p < 0.001 and p < 0.0001, respectively). The addition of myelin, 
however, did not alter arginase activity in any of the stimulations tested. Lastly, the myelin stimulants did not 
contain any endotoxin contamination that would confound our results (Supplemental Fig. 3). Collectively, this 
suggests that the pro-inflammatory effects of myelin on macrophage activation states are phenotype-specific.
Next, we sought to determine the cellular implications of these shifts in macrophage polarization states by 
applying BMDM conditioned media from these cells to a neuronal cell line (N2A) to determine the relative neu-
rotoxicity of each stimulation. In Fig. 2E, we observed that M1 neurotoxicity was again significantly potentiated 
by the addition of myelin, whereas CTL and M2 cell toxicity was unaffected by the addition of myelin.
cPLA2 inhibition blocks myelin’s pro-inflammatory potentiation of M1 macrophages. The 
activation of  cPLA2 by inflammatory stimuli is thought of as the primary rate-limiting step in the release of 
AA and the initiation of the production of various eicosanoids during the onset of inflammation. Given that 
we observed significant effects of myelin in macrophages in the presence of pro-inflammatory stimuli (LPS and 
IFN-γ), we hypothesized that  cPLA2 activation in M1 macrophages may be a key mediator of myelin’s cellular 
effects. To test this hypothesis, we targeted  cPLA2 in our in vitro model using the chemical inhibitor Palmityl 
trifluoromethylketone (PACOCF3) as used  previously28. As in our initial studies, we found myelin induced sig-
nificant increases in ROS, nitric oxide, and neurotoxicity when applied with an M1 stimulus, potentiating the 
M1 pro-inflammatory response (Fig. 3). Critically, application of the  cPLA2 inhibitor, PACOCF3, significantly 
reduced the myelin-mediated increases of ROS, nitric oxide, and neurotoxicity, indicating an important role for 
 cPLA2 in this system (Fig. 3). Interestingly, PACOCF3 did not influence arginase activity in any of the stimu-
lations tested (Fig. 3D and Supplemental Fig. 4D,H), suggesting that  cPLA2 is not linked to cellular arginase 
activity. Given that myelin did not previously affect ROS, nitric oxide, neurotoxicity, or arginase in the context 
Figure 1.  Macrophages can contain both myelin-derived lipids and active  cPLA2 28 days after spinal cord 
injury (SCI). Ten adult, 4-month-old C57/b female mice received a T9 75kdyn infinite horizons (IH) contusion 
SCI. (A–E) Representative example of TomL positive macrophages (blue) in injured white matter containing 
both lipid debris (green, BODIPY, staining for neutral lipids) and active p-cPLA2 (red) (imaged area is 
represented by box within spinal cord diagram). DAPI (white) was excluded from merged images. (F–J) 
Example of TomL positive macrophages (blue) in injured grey matter containing both lipid debris (green, 
BODIPY, staining for neutral lipids) and active p-cPLA2 (red). (K–O) Example of TomL positive macrophages 
(blue) in injured grey matter in the core of the injury epicenter containing both lipid debris (green, BODIPY, 
staining for neutral lipids) and active p-cPLA2 (red). (P–T) Example of TomL positive macrophages (blue) in 
uninjured tissue from sham animals with minimal lipid debris or active p-cPLA2 (red). Boxes indicate examples 
of triple positive cells. Maximum intensity projection confocal images. Scale bar in image p = 50 µm.
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of CTL or M2 stimulation, we would not expect  cPLA2 to influence these outcomes. Indeed, PACOCF3 had no 
significant effects on CTL or M2 simulations groups (Supplemental Fig. 4). Collectively these data suggest that 
 cPLA2 may play a key role in mediating myelin’s effects on pro-inflammatory macrophage activation.
Macrophage cytokine profiles indicate a mixed neuroinflammatory phenotype. Macrophages 
exist along a spectrum of activation states commonly simplified to pro- vs. anti-inflammatory states in vivo, or 
M1/M2 in vitro. While these terms are used for practical purposes, macrophages are further characterized by 
Figure 2.  Myelin potentiates pro-inflammatory macrophage activation in vitro. Bone marrow derived 
macrophages (BMDMs) were utilized to determine the function outcomes resulting from myelin debris 
application under three distinct activation states: M1 (IFN-γ and LPS), M2 (IL-4), or CTL (media, i.e. 
unstimulated). (A) Myelin stimulation significantly increased pro-inflammatory IL-12 cytokine levels 
relative to M1 alone (***p < 0.001), however myelin did not increase IL-12 in CTL or M2 treated cells. M1 
stimulations had increased IL-12 relative to CTL or M2 (###p < 0.001). (B) Following the stimulation BMDMs 
were washed and treated with 2 µM H2DCFDA for 25 min. Myelin stimulation increased ROS relative to 
M1 alone (***p < 0.001), however myelin did not increase ROS in CTL or M2 treated cells. M1 stimulations 
had increased ROS relative to CTL or M2 (###p < 0.001). (C) Nitric oxide levels in treated supernatants were 
examined using the Griess assay of nitrite accumulation. Myelin stimulation increased nitric oxide relative 
to M1 alone (***p < 0.001), however myelin did not increase nitric oxide in CTL or M2 treated cells. M1 
stimulations had increased nitric oxide relative to CTL or M2 (###p < 0.001). (D) Cell lysates were tested for 
arginase enzymatic activity. M2 macrophages had higher arginase activity relative to M1 and CTL (p < 0.001 
and p < 0.0001, respectively). The addition of myelin however did not significantly alter arginase activity in any 
of stimulations tested. (E) Supernatants were applied to a neuron culture (N2A cells) for 24 h to determine 
supernatant toxicity. Myelin stimulation increased neurotoxicity relative to M1 alone (*p < 0.05), however myelin 
did not increase neurotoxicity in CTL or M2 treated cells. M1 stimulations had increased ROS relative to CTL 
or M2 (###p < 0.001). Representative of 3 independent biological replications of both BMDMs and myelin source. 
*p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.05, ##p < 0.01, ###p < 0.001 mean ± SEM.
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many factors including morphology, surface markers, secreted cytokines, byproducts and functional outcomes. 
Our measures of neurotoxicity, IL-12, nitric oxide and ROS indicate a pathological phenotype; however, these 
are not comprehensive phenotypic indicators. To begin to address this complex phenotypic analysis we sought 
to measure additional inflammatory cytokines using a multiplex ELISA in our in vitro myelin/cPLA2 system. 
In line with our previous observations, M1 macrophages had significantly increased production of the pro-
inflammatory cytokines TNFα (p > 0.001) and CX3CL1 (p > 0.001) upon the addition of myelin (Fig. 4A,C), and 
for TNFα,  cPLA2 inhibition blunted this effect (p < 0.01) (Fig. 4B). Similarly, myelin significantly reduced the 
production of anti-inflammatory IL-10 in M1 cells, exacerbating their pro-inflammatory phenotype (p < 0.001) 
(Fig. 4E). Conversely, the pro-inflammatory cytokine IL-1β was significantly decreased in M1 cells following the 
addition of myelin (p < 0.001) (Fig. 4G). For the pro-inflammatory cytokine, IL-6, M1 cells were unaffected by 
the addition of myelin. Interestingly, for CX3CL1, myelin induced a small but significant increase in cytokine 
levels in CTL and M2 cells (Fig.  4C); IL-10 and IL-6 had similar trends in this regard, however, they were 
not statistically significant. Lastly, in some instances the  cPLA2 inhibitor (PACOCF3) alone induces significant 
cytokine shifts, decreasing CX3CL1 (p < 0.01) and increasing anti-inflammatory IL-10 (p < 0.001) (Fig. 4D,F), 
suggesting that  cPLA2 inhibition has anti-inflammatory effects outside the context of myelin stimulation. Inter-
estingly, when examining the effects of myelin and  cPLA2 inhibition specifically within CTL and M2 stimulation 
we observed statistically significant but biologically small, relative to M1, increases in both pro- (TNF-alpha, 
CX3CL1, IL-6) and anti-inflammatory (IL-10) cytokines suggesting myelin can induce a limited mixed pheno-
type in M2 and CTL groups (Supplemental Fig. 5). Collectively, these data indicate that myelin induces a mixed 
neuroinflammatory cytokine profile.
Myelin increases  cPLA2 activity in an activation state dependent manner. Myelin has long been 
proposed as an inflammatory stimulus in CNS models of  neuroinflammation10. Similarly,  cPLA2’s activation in 
response to a wide variety of chemokines and inflammatory signal has been well  documented29. Despite this, the 
formal hypothesis of whether myelin can directly increase macrophage  cPLA2 activation has not been directly 
tested. To this aim we performed a  PLA2 activity assay on cell lysates from CTL, M1, and M2 treated cells with or 
without myelin. Myelin increased  PLA2 activity in an activation state dependent manner, with M1 cells contain-
ing active  PLA2, which was further increased (*p < 0.05) with the addition of myelin (Fig. 5A–C). Conversely, 
 PLA2 activity in CTL and M2 cells was below the detection limit of the assay with or without the addition of 
myelin. To distinguish  cPLA2 activity from  iPLA2, cell lysates were incubated in Bromoenol Lactone to inhibit 
 iPLAs.  iPLA2 inhibition did not significantly reduce total  PLA2 activity in any of the groups tested indicating 
 cPLA2 is likely the primary source of this enzymatic activity (Fig. 5A–C).
Figure 3.  Inhibition of  cPLA2 with PACOCF3 reduces the pro-inflammatory effects of myelin on M1 
macrophages. BMDMs were grown and stimulated as in Fig. 2, with or without the addition of  cPLA2 
inhibitor, PACOCF3 (50 µM). (A)  cPLA2 inhibition reduced myelin mediated ROS increases in M1 (IFN-γ 
and LPS) macrophages. (B)  cPLA2 inhibition reduced myelin mediated nitric oxide production. (C)  cPLA2 
inhibition reduced the neurotoxic potential of M1 macrophages treated with myelin as determined by an 
MTT assay measurement of N2a cell viability. (D)  cPLA2 inhibition did not significantly alter arginase activity. 
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Discussion
The continual inflammatory response observed after spinal cord injury (SCI) is a primary mechanism impairing 
recovery, however, the factors contributing to this maladaptive response are poorly understood. One unique 
aspect of the CNS injury environment not present in peripheral injuries is the accumulation of large volumes of 
myelin debris within phagocytes at the lesion epicenter. Indeed, recent literature suggests that myelin may drive 
pro-inflammatory macrophage activation, supporting the notion that myelin accumulation within macrophages 
may be a key driver of the persistent pro-inflammatory macrophage response observed after  injury4,10,30. How-
ever, there are conflicting reports regarding the role of myelin on macrophage  activation7,31 and the mechanisms 
governing these discrepancies are not well understood. In this study we provided the proof of concept that 
myelin and  cPLA2 may play a key role in the prolonged pro-inflammatory macrophage activation thought to 
Figure 4.  Macrophage cytokine profiles indicate a mixed neuroinflammatory phenotype. Supernatants from 
treated BMDMs were collected to measure pro- and anti-inflammatory cytokine production in response to 
phenotype, myelin stimulation, and  cPLA2 inhibition with PACOCF3. (A, B) Myelin significanty increases the 
production of TNF-alpha in M1 cells, but has no effect on CTL and M2 cells.  cPLA2 inhibition significantly 
reduced myelin potentiation of M1 TNF-alpha production. (C, D) Myelin increases CX3CL1 in CTL, M1, 
and M2 cells.  cPLA2 inhibition significantly reduced this effect in M1 cells, but not under M1 and Myelin 
co-stimulation. (E, F) Myelin significantly decreased IL-10 production in M1 cells, but this effect was not 
reversed with  cPLA2 inhibition.  cPLA2 inhibition alone increased IL-10 production in M1 cells. (G, H) 
Myelin significantly reduced pro-inflammatory IL-1beta production in M1 cells, whereas CTL and M2 cells 
were unaffected.  cPLA2 inhibition did not alter this effect. (I, J) Pro-inflammatory IL-6 was not significantly 
altered by myelin or  cPLA2 inhibition. Refer to Supplementary Fig. 5 for CTL and M2  cPLA2 inhibition data. 
Representative of three biological replications. *p < 0.05 **p < 0.01, ***p < 0.001 mean ± SEM.
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impede semi-acute and chronic recovery after SCI. Specifically, we found that myelin potentiates macrophage 
polarization in an activation state-dependent manner. The addition of myelin alongside a pro-inflammatory M1 
macrophage stimulus (LPS and IFN-γ) further polarized pro-inflammatory activation as indicated by increased 
IL-12 production. Conversely, myelin had minimal effects on anti-inflammatory M2 (IL-4 stimulated) or control 
(unstimulated) macrophages. Similar patterns emerged when examining ROS, nitric oxide, arginase activity 
(indicative of M2 activation), and the neurotoxic potential of the macrophage supernatants. Inhibition of  cPLA2 
significantly blunted these harmful effects while arginase activity was unaffected. In vivo we observed ubiquitous 
myelin debris in, and around, macrophages expressing active  cPLA2, providing the key spatiotemporal evidence 
that  cPLA2 may also mediate the detrimental effects of myelin in macrophages after SCI.
Myelin and  cPLA2’s pro-inflammatory activities appear to be largely exclusive to the M1 phenotype as M2 
and CTL cells were unresponsive to myelin in most outcome measures. This interesting observation becomes 
clearer upon closer examination of  cPLA2 biology. AA is stored at the sn-2 position of membrane phospholipids 
where it is largely inactive. Enzymes from the lipid-cleaving phospholipase A2 family can release AA from the 
membranes, of which  cPLA2 is the most ubiquitous and widely studied due to its role in the targeted release of 
AA in response to a variety of  agonists29,32. Here, we demonstrate that myelin itself can induce increased  cPLA2 
activity. Once activated,  cPLA2 translocates from the cytosol to the membranes of the endoplasmic reticulum 
and nuclear envelope. These are the primary sites of  cPLA2 activity under homeostatic conditions, however, any 
alterations in  cPLA2 activity within the myelin-laden macrophage is currently  unknown33. It remains uncertain 
if myelin’s AA rich lipids could be a direct substrate for  cPLA2 or if these lipids could be trafficked within the cell 
to the endoplasmic reticulum and other membranes and be targeted. For each AA molecule released by  cPLA2, 
lysophosphatidylcholine is also produced, which is known to cause further demyelination and thus could con-
tribute to the prolonged myelin debris production observed after  SCI34. Basal  cPLA2 expression is increased in 
response to growth factors and inflammation in a variety of cell types, notably macrophages.  cPLA2 is activated 
by mitogen-activated protein kinase (MAPK) phosphorylation of its serine 505 sites in response to increased 
intracellular calcium, inflammatory stimuli, or ROS, many of which are substantially elevated after SCI (or in our 
in vitro model LPS and IFN-γ)14,35. The amount of AA released by activated  cPLA2 is then largely dependent on 
substrate availability, of which myelin could contribute substantial quantities to cellular stores in the membranes 
of the endoplasmic reticulum, nuclear envelope and other potential sites. Further, the oxidation of lipids in the 
membrane by ROS alters its viscosity further increasing AA availability to  cPLA235. Collectively, this suggests 
that the detrimental effects of myelin are restricted to the M1 phenotype, as only under these conditions could 
 cPLA2 become robustly activated and release AA.
Given the influential roles  cPLA2 activation and subsequent eicosanoid storms play in the initiation and 
resolution of inflammation, it is perhaps unsurprising that  cPLA2 has been previously studied in the context of 
SCI. Indeed, following SCI there is a substantial acute and sustained production of AA derived inflammatory 
 mediators36–38. One such study by NK Liu et al. found that pharmacologically or genetically targeting  cPLA2 
improved locomotor and anatomical recovery after SCI. Conversely, López-Vales et al. found  cPLA2 to have 
protective functions after SCI. Given the immensely diverse factors controlling  cPLA2 activation, AA release, 
and the downstream production of inflammatory mediators, it is quite possible that  cPLA2 has differential effects 
depending on the treatment paradigm or cell type (i.e. toxic mediators produced by M1 macrophages as in our 
Figure 5.  Myelin increases  cPLA2 activity in an activation state dependent manner. Cell lysates were collected 
from BMDM cultures to measure  cPLA2 activity following stimulation into CTL, M1, and M2 cells with 
or without myelin. Samples containing Bromoenol Lactone, an inhibitor of  iPLA2 were used to exclude the 
possibility of  iPLA2 contributing to enzymatic activity. (A) CTL treated cells had no discernable activity with or 
without myelin and Bromoenol Lactone. (B) M1 treated cells had a mean enzymatic activity of 4.88 nmol/min/
mL. Addition of myelin significantly increased  cPLA2 enzymatic activity (*p < 0.05). Addition of Bromoenol 
Lactone did not significantly alter enzyme activity. (C) M2 treated cells had no discernable activity with or 
without myelin and Bromoenol Lactone. Representative of three biological replications. *p < 0.05 **p < 0.01, 
***p < 0.001 mean ± SEM.
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in vitro model, and anti-inflammatory mediators in other cell types with different enzymatic processing of AA 
released by  cPLA2). Indeed, in the spinal cord after injury, in addition to macrophages, we observed appreciable 
 cPLA2 activity in many non-macrophage cell types within the lesion epicenter. Given the great heterogene-
ity of lipid signaling molecules downstream of  cPLA2, and differential capacities of each cell type to produce 
these mediators, it is uncertain whether  cPLA2 is mediating detrimental or beneficial effects in these other 
non-macrophage cell types. Prior studies targeting  cPLA2 have used a global approach to target  cPLA2 either 
genetically or with chemical inhibitors with conflicting  results14,34. Our results suggest that  cPLA2 plays a clear 
detrimental role in macrophage physiological responses to myelin, and thus future studies specifically target-
ing macrophage  cPLA2 in vivo may hold more therapeutic potential than the previous systemic approaches in 
which both detrimental and beneficial mechanisms are likely being affected. One important caveat to consider 
when using therapeutics targeting  cPLA2 is that many chemical inhibitors are cross-reactive with closely related 
phospholipases. In this study our  cPLA2 inhibitor of choice PACOCF3, for example, can also inhibit a related 
enzyme calcium-independent phospholipase A2  (iPLA2). While our data suggests that  iPLA2 is not contributing 
significantly to total  PLA2 activity at 24-h post-stimulation, it’s activities prior to cell lysis were not examined. 
Consequently, the influence of  iPLA2 cannot be ruled out in this study. Similarly, previous work has demonstrated 
that inhibiting  cPLA2 can influence the breakdown and phagocytosis of myelin during Wallerian  degeneration39. 
Continued work is needed to determine if such a mechanism could be occurring in the SCI Myelin-macrophage 
and our in vitro model.
Our results are consistent with a number of previous observations. Specifically, a 1994 publication by Wil-
liams et al. demonstrated that the treatment of microglia with myelin debris increased microglial activation as 
indicated by increased pro-inflammatory cytokine and ROS  production10. Next, Van der laan et al. demonstrated 
that myelin increases TNF-alpha and nitric oxide when applied to peritoneal macrophages. Lastly, Wang et al. 
(2014)4, observed similar increases in pro-inflammatory macrophage activation with myelin application to bone 
marrow-derived macrophages, and demonstrated the key role that this infiltrating macrophage population plays 
in clearing myelin debris in vivo after SCI.
While these papers support a mechanism linking myelin phagocytosis to the pro-inflammatory macrophage 
response observed after SCI, our results conflict with other data reporting anti-inflammatory actions of myelin 
in in vitro models of various CNS  disorders7,31. This suggests that the effects myelin has on macrophage activa-
tion may depend on the type of macrophage, stimulation timing, myelin source, dosage, and the CNS condition 
being modeled as discussed  previously11. Similarly, others have observed pro-inflammatory effects of myelin 
without a M1 co-stimulus4. Our data presented here indicate that the effect of myelin is phenotype specific, 
which may further account for these differences. For example, Kroner et al.,7 utilized a sequential approach: 
applying an M1 stimulus to the BMDMs, washed thoroughly, and then applied bovine-derived myelin. While 
this approach is certainly appropriate for some studies, it may not capture our phenotype-specific  cPLA2 medi-
ated inflammation, as  cPLA2 could need sustained LPS/IFN-γ to remain activated and exert its effects with 
myelin. Specifically,  cPLA2 activity is regulated by both a rapid transient calcium influx induced by inflammatory 
stimuli and its phosphorylation state allowing for complex regulation of either brief or sustained  activation40,41. 
Given this, sequential or simultaneous application of myelin and LPS/IFN-γ could induce  cPLA2 to activate and 
interact with myelin under very different regulatory conditions; however, further studies are needed to better 
understand how phenotype,  cPLA2 regulation, and methodological variation such as this synergize to produce 
differential responses to myelin. In doing so we could better understand the immune dysregulation leading to 
chronic inflammation after human SCI.
Our model utilized in this work has its own strengths and limitations in modeling the complex SCI inflamma-
tory response. First, we chose to use BMDM as our cell choice as recent literature has implicated this monocyte 
derived population as the primary mediator of myelin clearance, and as being more detrimental to recovery 
relative to  microglia4,42. Second, we utilized a high dose of myelin which was not overtly toxic yet provided excess 
myelin to overwhelm the cell’s phagocytic capacity over the 24-h stimulation window similar to what occurs after 
 SCI4–6,9. Lower doses may be better suited to shorter duration stimulations or studies investigating the effects of 
myelin upon binding to extracellular receptors. Third, our myelin preparations are from the same species and 
strain as the mice from which we collected the BMDMs (i.e. mouse myelin on mouse cells, and when feasible, 
myelin derived from the same mouse sacrificed for BMDM isolation). This was done to minimize any unintended 
cross-species immune effects. A limitation here, however, is that we used myelin derived from both brain and 
spinal cord tissue to yield sufficient myelin for our studies, it is possible that subtle differences in myelin com-
position between these sites could have differential effects. Similarly, the protein and lipid composition of CNS 
and PNS myelin differs and was not evaluated in this  study43. Fourth, we utilized a prolonged 24-h stimulation 
paradigm to allow for complete lipid loading of the cells as occurs in vivo. It is certainly possible that the results 
could be different at earlier time points. Similarly, studies interested in true chronic effects could adapt these 
protocols using cell lines to overcome the short lifespan of BMDMs. Fifth, we applied the myelin and stimulants 
at the same time and for the entire stimulation, as this is what likely occurs after SCI. Lastly, we applied myelin 
with multiple types of stimulates to begin to capture how myelin may affect macrophages across the spectrum of 
phenotypic states. An important caveat to this, however, is that we primarily investigated pathological BMDM 
features associated with impaired SCI recovery. There are likely other effects of myelin on CTL and M2 mac-
rophage physiology not captured in this study.
While in many ways our macrophage model closely replicates the cellular populations found after  SCI27, 
there are certainly other factors not utilized here in our model. Notably, TNF and iron are implicated as key 
environmental mediators of detrimental macrophage  activation7. Similarly, in vivo after SCI there are numer-
ous other factors that can influence macrophage activation, including cross talk between macrophages and 
microglia, T-cell responses, and damage associated molecular patterns released by necrotic  tissue44,45. While not 
investigated here, these are all likely important factors contributing to pro-inflammatory macrophage activation 
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in myelin-laden macrophages and represent an important caveat in extrapolating our results to the human SCI 
condition. Similarly, while the data presented here implicate  cPLA2 as an important regulator of myelin’s activ-
ity, other cellular mechanisms are certainly involved. Myelin uptake/phagocytosis, for example, is clearly a key 
step prior to any intracellular mechanism. Injection of myelin directly into the spinal cord previously by Sun 
and colleagues was found to induce leukocyte chemoattraction, however, this effect was lost in CR3 KO animals 
with deficient phagocytic capacity. Next, they implicated the FAK/Akt/NF-κB signaling cascade as a mediator of 
myelin’s  activity46. These observations are certainly compatible with our current observations as the NF-κB signal-
ing cascade is activated by similar stimuli as the  cPLA2 signaling cascade including our LPS in-vitro stimulant. 
Interestingly, activation of NF-κB by myelin may even drive increased  cPLA2 expression, further demonstrating 
the intertwined nature of many proposed  mechanisms47. Collectively, this demonstrates the need for continued 
investigation of these pathways to identify a clinically viable treatment for SCI in the human condition.
Our in vitro data suggest that myelin debris potentiates pro-inflammatory functions specifically within the 
M1 macrophage population. Intriguingly, the time course of peripheral macrophage infiltration and initial 
clearance of myelin debris between 3 and 7 days post-SCI correlates with the peak presence of M2 macrophage 
activation markers, which then progressively drop as the cells shift to a pronounced and prolonged M1 activation 
 state1,2. By chronic time points only M1 markers can be detected, indicative of the prolonged pro-inflammatory 
macrophage activation thought to impede  recovery4,6,9. Here we demonstrate that  cPLA2 is present within myelin-
laden macrophages well into chronic time points. Together with our in vitro data, this provides the proof of 
concept that myelin and  cPLA2 may play a key role in the prolonged pro-inflammatory macrophage activation 
thought to impede semi-acute and chronic recovery after SCI. Collectively this highlights macrophage  cPLA2 
activity as a potential key mediator of the neuroinflammatory response after SCI and thereby warrants continued 
investigation as a therapeutic target.
Conclusions
Spinal cord injury (SCI) produces chronic intraspinal inflammation consisting of resident microglia and infiltrat-
ing monocytes. These chronically activated SCI macrophages adopt a persistent pro-inflammatory, pathological 
state that potentiates secondary damage and impairs SCI  recovery1,3. The mechanisms driving chronic mac-
rophage activation in SCI are poorly understood. Here we implicate myelin debris and  cPLA2 as key mediators 
of pathological macrophage activation. In vitro we found that the effects of myelin on macrophage activation are 
phenotype-specific, with myelin potentiating only pro-inflammatory (LPS + INF-γ; M1) macrophage activation, 
whereas myelin had no pro-inflammatory effect on unstimulated or anti-inflammatory (IL-4; M2) macrophages. 
Inhibition of  cPLA2 significantly reduced the detrimental effects of myelin on M1 macrophages, implicating 
 cPLA2 as a key regulator of maladaptive macrophage activation. In vivo we observed ubiquitous myelin debris 
in, and around, macrophages expressing active  cPLA2 providing the key spatiotemporal evidence that  cPLA2 
may also mediate the detrimental effects of myelin in macrophages after SCI. Collectively, this establishes a novel 
mechanism driving detrimental macrophage activation and provides key evidence identifying macrophage  cPLA2 
activity as a therapeutic target to improve recovery after SCI.
Data availability
The datasets analyzed during the current study are available from the corresponding author upon request. In vivo 
data will be made available through the Open Data Commons for Spinal Cord Injury (ODC-SCI: https:// scicr 
unch. org/ odc- sci).
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